AffiDX SARS-CoV-2 Antigen Lateral Flow Test Update

RNS Number : 0838Y
Avacta Group PLC
10 May 2021
 

10 May 2021

Avacta Group plc

("Avacta" or "the Group")

 

AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Update

 

Submission of Declaration of Conformity for CE mark for Avacta's rapid antigen test

 

Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION platforms, is pleased to announce that the Declaration of Conformity for CE mark of its AffiDX® SARS-CoV-2 antigen rapid test for professional use has been submitted to the Medicines and Healthcare products Regulatory Agency ("MHRA") through the Group's partner Mologic Limited.

 

The Group has developed a SARS-CoV-2 antigen lateral flow test using its Affimer® platform to detect the coronavirus spike antigen and recently announced data from a clinical study on 98 positive COVID-19 samples that demonstrate excellent performance in identifying the SARS-CoV-2 virus across a broad range of viral loads.

 

These data have now been combined with stability and other performance data and a submission of the Declaration of Conformity for CE marking of the AffiDX® SARS-CoV-2 antigen lateral flow test for professional use has now been made to the MHRA.

 

The Group expects to receive confirmation of the registration of the AffiDX® in-vitro diagnostic device in the coming days, which will allow the Group to immediately place the test on the market.

 

Dr Alastair Smith, Chief Executive of Avacta Group commented:

"I am absolutely delighted to have reached this significant milestone for the Diagnostics Division and Avacta Group.

 

"I am very proud of the quality and performance of Avacta's AffiDX® antigen test. As part of the recent clinical study the same clinical samples were tested with two leading, commercially available lateral flow antigen tests, and the data show that the AffiDX® test had better clinical sensitivity across the range of Ct values tested and, in particular, at lower viral loads.

 

"We are very excited by the potential of this high quality SARS-CoV-2 rapid antigen test and the interest that we have received for it from potential commercial partners, distributors and end users. We are looking forward to receiving confirmation of the registration from MHRA in the coming days allowing the Group to immediately place the test on the market. "

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

 

- Ends -

 

For further information from Avacta Group plc, please contact:

 

Avacta Group plc

Tel: +44 (0) 844 414 0452

Alastair Smith, Chief Executive Officer

www.avacta.com

Tony Gardiner, Chief Financial Officer




Stifel Nicolaus Europe Limited (Nominated Adviser and Sole Corporate Broker)

Tel: +44 (0) 207 710 7600

Nicholas Moore / Nick Adams / Fred Walsh / Ben Maddison

www.stifel.com



FTI Consulting (Financial Media and IR)

Tel: +44 (0) 203 727 1000

Simon Conway / Stephanie Cuthbert

Avacta.LS@fticonsulting.com



Zyme Communications (Trade and Regional Media)

Tel: +44 (0) 7787 502 947

Katie Odgaard

katie.odgaard@zymecommunications.com

 

About Avacta Group plc - https://www.avacta.com

Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer® biologics and pre|CISION tumour targeted chemotherapies.

 

The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the reliance on an animal's immune response; poor specificity in many cases; their large size, complexity and high cost of manufacture.

 

Avacta's pre|CISION targeted chemotherapy platform releases active chemotherapy in the tumour, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these powerful anti-cancer treatments.

 

The Group comprises two divisions: The therapeutics development activities are based in Cambridge, UK and the Group is generating near-term revenues from Affimer reagents for diagnostics, bioprocessing and research, through a separate diagnostics business unit based in Wetherby, UK.

 

Avacta's Diagnostics Division works with partners world-wide to develop bespoke Affimer reagents for third party products. The Group is also developing an in-house pipeline of Affimer-based diagnostic assays including the AffiDX ® SARS-CoV-2 Lateral Flow Rapid Antigen Test and an AffiDX ® BAMS SARS-CoV-2 Assay in partnership with Adeptrix Inc.

 

Avacta's Therapeutics Division is addressing a critical gap in current cancer treatment - the lack of a durable response to current immunotherapies experienced by most patients. By combining its two proprietary platforms the Group is building a wholly owned pipeline of novel cancer therapies deigned to be effective for all cancer patients. In 2021 Avacta will commence a phase 1 first-in-human, open label, dose-escalation and expansion study of AVA6000 Pro-doxorubicin, the Group's lead pre|CISION prodrug, in patients with locally advanced or metastatic selected solid tumours.

 

Avacta has established drug development partnerships with pharma and biotech, including a research collaboration with ModernaTX,Inc. (formerly Moderna Therapeutics Inc.), a multi-target deal with LG Chem worth up to $400m, a joint venture in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies incorporating Affimer immune-modulators, a partnership with ADC Therapeutics to develop Affimer-drug conjugates and a collaboration with Point Biopharma to develop radiopharmaceuticals based on the pre|CISION platform. Avacta continues to actively seek to license its proprietary platforms in a range of therapeutic areas.

 

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDGCGDUXXBDGBG
UK 100

Latest directors dealings